Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -7.59% | 9.94% | 17.55% | -10.35% | 400.97% |
| Gross Profit | 7.59% | -9.94% | -17.55% | 8.52% | -400.97% |
| SG&A Expenses | 3.58% | -27.02% | 0.05% | -24.52% | -14.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.37% | -8.72% | 5.84% | -17.13% | -3.59% |
| Operating Income | 24.37% | 8.72% | -5.84% | 16.25% | 3.59% |
| Income Before Tax | 30.70% | 4.73% | -6.27% | 22.00% | -2.46% |
| Income Tax Expenses | 3,380.69% | -48.84% | -95.49% | 19.16% | -81.43% |
| Earnings from Continuing Operations | 20.23% | 4.93% | -5.92% | 21.86% | -1.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.23% | 4.93% | -5.92% | 21.86% | -1.06% |
| EBIT | 24.37% | 8.72% | -5.84% | 16.25% | 3.59% |
| EBITDA | 24.38% | 8.78% | -5.86% | 16.28% | 3.69% |
| EPS Basic | 56.76% | 54.48% | 31.71% | 48.12% | 20.06% |
| Normalized Basic EPS | 62.45% | 54.39% | 31.51% | 48.19% | 18.91% |
| EPS Diluted | 56.76% | 54.48% | 31.71% | 48.12% | 20.06% |
| Normalized Diluted EPS | 62.45% | 54.39% | 31.51% | 48.19% | 18.91% |
| Average Basic Shares Outstanding | 84.46% | 108.89% | 55.13% | 50.64% | 26.39% |
| Average Diluted Shares Outstanding | 84.46% | 108.89% | 55.13% | 50.64% | 26.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |